Dual-action GIP/GLP-1 for enhanced weight loss
Pricing varies by protocol
A dual GIP/GLP-1 receptor agonist delivered as a once-weekly injection. Tirzepatide targets two incretin pathways simultaneously for enhanced appetite regulation and metabolic improvement. This dual mechanism may produce greater appetite suppression and metabolic benefits compared to single-pathway agents. Prescribed and monitored by your clinician with individualized dose titration.
Licensed Providers · Lab-Guided · Ongoing Support
This treatment may be right for you if you identify with any of the following:
Explore alternative treatments your provider may recommend
Take the first step with a clinician-guided evaluation. Personalized protocols, compounded medications, ongoing support.
Take the Weight Loss QuizTirzepatide Injection at RenewRx starts at $250/month. That includes your provider consultation, protocol design, and lab monitoring every 90 days — there is no separate membership fee stacked on top. Final pricing depends on the dose and protocol your clinician prescribes after reviewing your bloodwork.
RenewRx dispenses compounded tirzepatide from a licensed 503A pharmacy. Compounded medications are prepared for an individual patient and are not FDA-approved. The FDA-approved branded version is Zepbound and Mounjaro. We'd rather tell you that plainly than let you assume otherwise — your provider will walk you through what it means before you start.
A once-weekly subcutaneous injection you give yourself at home, using a small insulin-style needle. Your provider starts you at a low dose and titrates upward over several months based on your response and tolerance.
Most patients notice reduced appetite within the first one to two weeks. Measurable weight loss typically appears within the first month, with results continuing to build over three to six months as your dose is titrated.
The most common side effects are gastrointestinal — nausea, constipation, diarrhea, and reflux — and they're usually worst right after a dose increase, easing as your body adjusts. Slower titration usually helps. Serious side effects are uncommon but real; your provider reviews them with you before you start. Important: GLP-1 medications carry a boxed warning for thyroid C-cell tumors. They are not appropriate for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Tell your provider if either applies to you.
Yes. Every RenewRx protocol begins with a lab panel reviewed by a licensed provider before anything is prescribed. We won't write a prescription off a questionnaire alone. Labs are rechecked every 90 days so your dose is adjusted to how you're actually responding — not to how you're expected to respond.
Semaglutide activates one receptor pathway (GLP-1). Tirzepatide activates two (GLP-1 and GIP). In head-to-head trials of the branded drugs, the dual-pathway approach produced greater average weight loss. That doesn't automatically make it the right choice for you — your labs, tolerance, and history decide that.
Most of the benefit fades once you stop, because these therapies manage a condition rather than cure it. That said, the goal isn't to keep you on medication forever — your provider will talk with you about duration, tapering, and what an exit looks like. If a clinic never raises that conversation, ask why.
No contract, and no lock-in. Our protocols are structured as three-month programs because that's the window where the physiology actually shows up — hormone and peptide therapy needs time, plus at least one lab recheck, before anyone can honestly say whether it's working. You're committing to giving the protocol a fair trial, not to a contractual obligation.
Answers reviewed and approved by RenewRx clinical staff. This information is educational and is not medical advice or a substitute for evaluation by a licensed provider. Pricing reflects current protocols and may change.
